| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
|
Am J Kidney Dis
|
2006
|
4.26
|
|
2
|
Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.
|
Clin J Am Soc Nephrol
|
2010
|
4.06
|
|
3
|
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.
|
Circulation
|
2003
|
3.89
|
|
4
|
A role for uric acid in the progression of renal disease.
|
J Am Soc Nephrol
|
2002
|
3.77
|
|
5
|
Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.
|
Am J Med
|
1984
|
3.05
|
|
6
|
Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects.
|
Hypertens Res
|
2001
|
2.35
|
|
7
|
Relationship of uric acid with progression of kidney disease.
|
Am J Kidney Dis
|
2007
|
2.26
|
|
8
|
J-shaped mortality relationship for uric acid in CKD.
|
Am J Kidney Dis
|
2006
|
1.88
|
|
9
|
Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
|
Am J Kidney Dis
|
2015
|
1.77
|
|
10
|
Association of uric acid with change in kidney function in healthy normotensive individuals.
|
Am J Kidney Dis
|
2010
|
1.65
|
|
11
|
Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes.
|
Eur J Clin Invest
|
2001
|
1.40
|
|
12
|
Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients.
|
Nephrol Dial Transplant
|
2004
|
1.33
|
|
13
|
Uric acid levels predict future development of chronic kidney disease.
|
Am J Nephrol
|
2011
|
1.10
|
|
14
|
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
|
Clin Exp Nephrol
|
2015
|
1.03
|
|
15
|
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
|
J Clin Rheumatol
|
2011
|
0.88
|
|
16
|
Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis.
|
J Ren Nutr
|
2012
|
0.82
|
|
17
|
Natural history and etiology of hyperuricemia following pediatric renal transplantation.
|
Pediatr Nephrol
|
1995
|
0.80
|
|
18
|
Is It Time to Start Treating Asymptomatic Hyperuricemia?
|
Am J Kidney Dis
|
2015
|
0.76
|
|
19
|
Study protocol for a prospective observational study to investigate the role of luminal pressure on arteriovenous fistula maturation.
|
Medicine (Baltimore)
|
2019
|
0.75
|